<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918203</url>
  </required_header>
  <id_info>
    <org_study_id>13900</org_study_id>
    <secondary_id>CP15-0804</secondary_id>
    <secondary_id>I5B-IE-JGDB</secondary_id>
    <nct_id>NCT00918203</nct_id>
  </id_info>
  <brief_title>A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Randomized Phase 2 Study of Human Anti-PDGFRÎ± Monoclonal Antibody (IMC-3G3) With Paclitaxel/Carboplatin or Paclitaxel/Carboplatin Alone in Previously Untreated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if participants with untreated locally advanced or
      metastatic non-small cell lung cancer have a better outcome when treated with olaratumab in
      combination with paclitaxel/carboplatin then when treated with paclitaxel/carboplatin alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the progression-free survival (PFS) in
      previously untreated participants with Stage IIIB/IV non-small cell lung cancer (NSCLC)
      treated with olaratumab plus paclitaxel and carboplatin versus paclitaxel and carboplatin in
      the first-line metastatic setting.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Baseline to Measured PD or Death From Any Cause (Up to 31 Months)</time_frame>
    <description>PFS is defined as the time from the day of randomization to the first evidence of progression by RECIST version 1.1, or death from any cause. Participants who died without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress and were subsequently lost to follow-up had their data censored at the day of their last tumor assessment. If there was no radiologic assessment at baseline or post baseline, participants were censored at the date of randomization. If death or progressive disease (PD) occurred after 2 or more consecutive missing radiographic visits, censoring occurred at the date of the last radiographic visit prior to the missed visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)</measure>
    <time_frame>Baseline to Study Completion (Up to 43 Months)</time_frame>
    <description>A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Olaratumab Administered at a More Rapid Rate (25mg/Min With Minimum Infusion Time of 30 Minutes), Determined by Number of Participants With Treatment Related Adverse Events</measure>
    <time_frame>Up to 43 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to Death From Any Cause (Up to 31 Months)</time_frame>
    <description>Overall survival is defined as the time from date of randomization to the date of death from any cause. If the participant is alive at the end of the follow-up period or is lost to follow-up, OS was censored on the last date the participants is known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) Objective Tumor Response Rate (ORR)</measure>
    <time_frame>Baseline to Measured PD or Study Discontinuation (Up to 31 Months)</time_frame>
    <description>The ORR is equal to the percentage of participants achieving a best overall response of partial response or complete response (PR + CR), according to RECIST version 1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes must have reduction in short axis to &lt;10 millimeter (mm) and normalization of tumor marker level of non-target lesions; PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions; PD was defined as having at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase above nadir; Stable Disease (SD) was defined as small changes that did not meet above criteria. Participants who had no post baseline tumor assessments were considered non-responders and included in the denominator when calculating response rate. Percentage of participants=(number of participants with CR+PR/total number of participants)*100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Duration of Response</measure>
    <time_frame>First Criteria Met for CR or PR to Measured PD Start of Other Antitumor Therapy or Death From Any Cause (Up to 31 Months)</time_frame>
    <description>The duration of overall response is measured from the time measurement criteria are first met for Complete Response (CR)/Partial Response (PR) (whichever is first recorded) until the first date that the criteria for PD are met (taking as a reference for PD the smallest measurement recorded since the treatment started), initiation of other/additional antitumor therapy is first reported, or death, is objectively documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of Olaratumab</measure>
    <time_frame>Cycle 1: Days 1, 8, and 15 pre- and post-infusion of Olaratumab; Cycles 2-6: day 1 only, pre- and post-infusion of Olaratumab</time_frame>
    <description>Pharmacodynamics of Olaratumab was determined by analysis of pharmacodynamic markers vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Olaratumab Antibodies</measure>
    <time_frame>Baseline to Study Completion (Up to 8 Months)</time_frame>
    <description>Participants with Treatment Emergent (TE) anti-olaratumab antibodies were participants with a 4-fold increase (2 dilutions) increase over a positive baseline antibody titer or for a negative baseline titer, a participant with an increase from the baseline to a level of 1:20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) - Area Under the Curve (AUC) 0-168 of Olaratumab</measure>
    <time_frame>Cycle 3, Day 1: Predose, 30 minutes (min), 1.5 hours (hrs), 24,48,96,168 Hrs Post Dose</time_frame>
    <description>AUC(0-168) = area under the concentration versus time curve from time zero to 168 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK - Maximum Concentration (Cmax) of Olaratumab</measure>
    <time_frame>Cycle 3, Day 1: Predose, 30 min, 1.5 hrs, 24,48,96,168 Hrs Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK - Half-Life (t1/2) of Olaratumab</measure>
    <time_frame>Cycle 3, Day 1: Predose, 30 min, 1.5 hrs, 24,48,96,168 Hrs Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK - Clearance (Cl) of Olaratumab</measure>
    <time_frame>Cycle 3, Day 1: Predose, 30 min, 1.5 hr, 24,48,96,168 Hrs Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK - Steady State Volume of Distribution (Vss) of Olaratumab</measure>
    <time_frame>Cycle 3, Day 1: Predose, 30 min, 1.5 hrs, 24,48,96,168 Hrs Post Dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel + Carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(Initial 4-6 cycles) Paclitaxel 200 milligram/square meter (mg/m2) over 3 hrs (Day 1) Carboplatin Area Under Concentration (AUC)=6 (Day 1) of each 21-day cycle (Initial 4-6 cycles) Paclitaxel 200 mg/m2 over 3 hrs (Day 1) Carboplatin AUC=6 (Day 1) of each 21-day cycle
Participants who experience progressive disease may cross over to olaratumab monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaratumab + Paclitaxel + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Initial 4-6 cycles)
Olaratumab 15 milligrams/kilogram (mg/kg) over 30 mins (Days 1 and 8) plus Paclitaxel 200 mg/m2 over 3 hrs (Day 1) Carboplatin AUC=6 (Day 1) of each 21-day cycle
Participants can remain on study after completing chemotherapy and receive olaratumab monotherapy on Days 1 and 8, provided there is ongoing evidence of clinical benefit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Olaratumab</intervention_name>
    <description>15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered intravenously (IV) at 25 milligram/minute (mg/min), with a minimum infusion time of 30 minutes.</description>
    <arm_group_label>Olaratumab + Paclitaxel + Carboplatin</arm_group_label>
    <other_name>LY3012207</other_name>
    <other_name>IMC-3G3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>200 mg/m2 is then administered IV over 3 hours</description>
    <arm_group_label>Paclitaxel + Carboplatin</arm_group_label>
    <arm_group_label>Olaratumab + Paclitaxel + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
    <arm_group_label>Paclitaxel + Carboplatin</arm_group_label>
    <arm_group_label>Olaratumab + Paclitaxel + Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The participants has histologically or cytologically confirmed Non-Small Cell Lung
             Cancer (NSCLC)Stage IIIB with effusion. Mixed Non-Small Cell Lung Cancer (NSCLC)
             tumors will be categorized by the predominant cell type. Primary or metastatic site
             may be used for histology

          2. For squamous cell histology or for centrally located mediastinal masses (&lt; 3 cm from
             the carina) identified by computed tomography scan (CT) or chest x-ray, the
             participant must undergo a magnetic resonance imaging (MRI) of the chest or I.V.
             contrast CT scan within 3 weeks of randomization, to exclude major airway or blood
             vessel invasion (in the investigator's opinion) by cancer

          3. The participant has measurable disease (Tumors within a previously irradiated field
             will be designated as &quot;nontarget&quot; lesions unless progression is documented or a biopsy
             is obtained to confirm persistence at least 90 days following completion of radiation
             therapy

          4. The participant's Eastern Cooperative Oncology Group (ECOG) performance status is 0-1

          5. The participant's age at the time of study entry is â¥ 18 years

          6. The participant has adequate hematologic function as defined by an absolute neutrophil
             count (ANC) â¥ 1500/Î¼L, hemoglobin â¥ 9.5 g/dL, and a platelet count â¥ 100,000/Î¼L
             obtained within 2 weeks prior to randomization

          7. The participant has adequate hepatic function as defined by a total bilirubin â¤ 1.5
             mg/dL, and aspartate transaminase (AST) and alanine transaminase (ALT) â¤ 3.0 Ã the
             upper limit of normal (ULN), or â¤ 5 Ã the ULN in the presence of known liver
             metastases)

          8. The participant has adequate renal function as defined by serum creatinine â¤ 1.5 Ã the
             institutional ULN. If creatinine is above the ULN, the patient's creatinine clearance
             (CrCl) is â¥ 60 mL/min

          9. The participant has urinary protein â¤ 1+ on dipstick or routine urinalysis; if urine
             dipstick or routine analysis is â¥ 2+, a 24-hour urine for protein must demonstrate &lt; 1
             g of protein in 24 hours to allow participation

         10. The participant has adequate coagulation function, as defined by international
             normalized ratio (INR) â¤ 1.5 and a partial thromboplastin time (PTT) â¤ 5 seconds above
             ULN if not receiving anticoagulation therapy. Participants on full-dose
             anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight
             heparin, have therapeutic INR, no active bleeding (defined as within 14 days
             randomization) and no pathological condition that carries a high risk of bleeding (eg,
             tumor involving major vessels or known varices)

         11. Because the teratogenicity of Olaratumab is not known, women of childbearing potential
             (WOCBP) and sexually active males must agree to use adequate contraception (hormonal
             or barrier method of birth control; abstinence) prior to randomization and for the
             duration of study participation

         12. The participant has resolution to Grade â¤ 1 by the National Cancer Institute Common
             Terminology Criteria for Adverse Events, Version 4 (NCI-CTCAE v 4.02) of all
             clinically significant toxic effects of prior locoregional therapy, surgery,
             chemoembolization, or other anticancer therapy. The exceptions for such effects are
             events that pertain to the lab values found elsewhere in these inclusion criteria.
             (For example, criterion # 6 states that a patient with hemoglobin â¥ 9.5 g/dL is
             considered eligible, even though NCI-CTCAE v 4.02 defines this value as Grade 2
             anemia.)

         13. The participant has a life expectancy of â¥ 3 months

         14. The participant has provided signed informed consent

        Exclusion Criteria:

          1. The participant has untreated central nervous system (CNS) metastases. Participants
             are eligible if they are clinically stable, off all steroids after cranial irradiation
             (whole brain radiation therapy, focal radiation therapy, stereotactic
             radiosurgery)ending at least 2 weeks prior to randomization, or after surgical
             resection performed at least 4 weeks prior to randomization

          2. The participant has radiologically documented evidence of major blood vessel invasion
             or encasement by cancer, or of intratumor cavitation

          3. The participant received prior systemic chemotherapy or biologic therapy (eg
             erlotinib) for Stage IIIB/IV NSCLC outside of the adjuvant setting. Participants who
             received prior cytotoxic chemotherapy or biologic therapy in the adjuvant setting will
             not be excluded based on such therapy

          4. The participant has a history of another primary cancer, with the exception of a)
             curatively resected nonmelanomatous skin cancer b) curatively treated cervical
             carcinoma in situ c)other primary solid tumor treated with curative intent, no known
             active disease present, and no treatment administered during the last 3 years prior to
             randomization

          5. The participant is receiving concurrent treatment with other anticancer therapy,
             including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy,
             chemo-embolization, targeted therapy, or an investigational agent

          6. The participant has an uncontrolled intercurrent illness including, but not limited
             to, ongoing or active infection requiring parenteral antibiotics, symptomatic
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric
             illness/social situations that would limit compliance with study requirements

          7. The participant has an uncontrolled thrombotic or hemorrhagic disorder

          8. The participant has a history of gross hemoptysis (defined as bright red blood or â¥
             1/2 teaspoon) within 2 months of randomization

          9. The participant has a serious non-healing wound, ulcer, or bone fracture within 28
             days prior to randomization

         10. The participant has undergone major surgery within 28 days prior to randomization

         11. The participant has received adjuvant chemotherapy 21 days prior to randomization or
             has participated in clinical trials of experimental agents within 28 days prior to
             randomization

         12. The participant has an elective or a planned major surgery to be performed during the
             course of the trial

         13. The participant has peripheral neuropathy â¥ Grade 2 NCI-CTCAE v 4.02

         14. The participant has known human immunodeficiency virus (HIV) positivity

         15. The participant, if female, is pregnant or lactating

         16. The participant has received previous therapy with any agent that targets platelet
             derived growth factor (PDGF) or platelet derived growth factor receptor (PDGFR)

         17. The participant has a known allergy to any of the treatment components

         18. The participant has a history of allergic reactions attributed to compounds of
             chemical or biologic composition similar to that of Olaratumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Highland</city>
        <state>California</state>
        <zip>92346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>20854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Massillon</city>
        <state>Ohio</state>
        <zip>44646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2009</study_first_submitted>
  <study_first_submitted_qc>June 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2009</study_first_posted>
  <results_first_submitted>November 18, 2016</results_first_submitted>
  <results_first_submitted_qc>November 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2017</results_first_posted>
  <disposition_first_submitted>April 25, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 25, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 13, 2014</disposition_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung neoplasms</keyword>
  <keyword>IMC-3G3</keyword>
  <keyword>carboplatin</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>PDGFr</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Olaratumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants who had evidence of progressive disease (PD), died or crossover to Olaratumab were considered to have completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olaratumab + Paclitaxel + Carboplatin</title>
          <description>Olaratumab: 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered IV at 25mg/min, with a minimum infusion time of 30 minutes.
Paclitaxel 200 milligram/square meter (mg/m2) over 3 hrs (Day 1) Carboplatin Area Under Concentration (AUC)=6 (Day 1) of each 21-day cycle
Paclitaxel 200 mg/m2 over 3 hrs (Day 1) Carboplatin AUC=6 (Day 1) of each 21-day cycle
Participants who experience progressive disease may cross over to olaratumab monotherapy.
Paclitaxel: 200 mg/m2 is then administered intravenously (IV) over 3 hours
carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
        </group>
        <group group_id="P2">
          <title>Paclitaxel + Carboplatin</title>
          <description>Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
        </group>
        <group group_id="P3">
          <title>Crossover to Olaratumab Monotherapy</title>
          <description>Olaratumab was administered IV at 15 mg/kg on Day 1 and Day 8 every 3 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment With or Without Olaratumab</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Therapy Started</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never Treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Off Study Treatment/Alive</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>On Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Crossover to Olaratumab Monotherapy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="17">16 participants crossed over to olaratumab after PD and 1 participant of symptomatic deterioration.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Therapy Started</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All phase 2 participants who were randomized and received any dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Olaratumab + Paclitaxel + Carboplatin</title>
          <description>Olaratumab 15 mg/kg over 30 mins (Days 1 and 8) plus Paclitaxel 200 mg/m2 over 3 hrs (Day 1) Carboplatin AUC=6 (Day 1) of each 21-day cycle
Participants can remain on study after completing chemotherapy and receive olaratumab monotherapy on Days 1 and 8, provided there is ongoing evidence of clinical benefit.
Olaratumab: 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered IV at 25mg/min, with a minimum infusion time of 30 minutes.
Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
        </group>
        <group group_id="B2">
          <title>Paclitaxel + Carboplatin</title>
          <description>Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="131"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.6" spread="10.77"/>
                    <measurement group_id="B2" value="63.8" spread="9.67"/>
                    <measurement group_id="B3" value="63.7" spread="10.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group Performance Status (ECOG PS)</title>
          <description>ECOG performance status classified participants according to their functional impairment. Scores ranged from 0 (fully active) to 5 (death).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ECOG PS 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG PS 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor Case Report Form (CRF)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non-Squamous Cell Carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Squamous Cell Carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS)</title>
        <description>PFS is defined as the time from the day of randomization to the first evidence of progression by RECIST version 1.1, or death from any cause. Participants who died without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress and were subsequently lost to follow-up had their data censored at the day of their last tumor assessment. If there was no radiologic assessment at baseline or post baseline, participants were censored at the date of randomization. If death or progressive disease (PD) occurred after 2 or more consecutive missing radiographic visits, censoring occurred at the date of the last radiographic visit prior to the missed visits.</description>
        <time_frame>Baseline to Measured PD or Death From Any Cause (Up to 31 Months)</time_frame>
        <population>All randomized participants who received any dose of study drug. Participants censored: paclitaxel + carboplatin = 13, olaratumab + paclitaxel + carboplatin = 20, and crossover to olaratumab = 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Olaratumab + Paclitaxel + Carboplatin</title>
            <description>Olaratumab: 15 mg/kg of Olaratumab on Days 1 and 8 of each 21-day cycle, administered IV at 25mg/min, with a minimum infusion time of 30 minutes.
Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel + Carboplatin</title>
            <description>Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Crossover to Olaratumab</title>
            <description>Olaratumab monotherapy administered on Days 1 and 8 of each 21-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS)</title>
          <description>PFS is defined as the time from the day of randomization to the first evidence of progression by RECIST version 1.1, or death from any cause. Participants who died without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress and were subsequently lost to follow-up had their data censored at the day of their last tumor assessment. If there was no radiologic assessment at baseline or post baseline, participants were censored at the date of randomization. If death or progressive disease (PD) occurred after 2 or more consecutive missing radiographic visits, censoring occurred at the date of the last radiographic visit prior to the missed visits.</description>
          <population>All randomized participants who received any dose of study drug. Participants censored: paclitaxel + carboplatin = 13, olaratumab + paclitaxel + carboplatin = 20, and crossover to olaratumab = 4.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" lower_limit="16.4" upper_limit="23.6"/>
                    <measurement group_id="O2" value="19.0" lower_limit="15.3" upper_limit="25"/>
                    <measurement group_id="O3" value="8.3" lower_limit="5.0" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2133</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)</title>
        <description>A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.</description>
        <time_frame>Baseline to Study Completion (Up to 43 Months)</time_frame>
        <population>All randomized participants who received any dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Olaratumab + Pacilitaxel + Carboplatin</title>
            <description>Olaratumab: 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered IV at 25mg/min, with a minimum infusion time of 30 minutes.
Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel + Carboplatin</title>
            <description>Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Crossover to Olaratumab</title>
            <description>Olaratumab monotherapy administered on Days 1 and 8 of each 21-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)</title>
          <description>A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.</description>
          <population>All randomized participants who received any dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE's</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Olaratumab Administered at a More Rapid Rate (25mg/Min With Minimum Infusion Time of 30 Minutes), Determined by Number of Participants With Treatment Related Adverse Events</title>
        <time_frame>Up to 43 Months</time_frame>
        <population>All randomized participants who received any dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Olaratumab + Paclitaxel + Carboplatin</title>
            <description>Olaratumab: 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered IV at 25mg/min, with a minimum infusion time of 30 minutes.
Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel + Carboplatin</title>
            <description>Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Crossover to Olaratumab</title>
            <description>Olaratumab monotherapy administered on Days 1 and 8 of each 21-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Olaratumab Administered at a More Rapid Rate (25mg/Min With Minimum Infusion Time of 30 Minutes), Determined by Number of Participants With Treatment Related Adverse Events</title>
          <population>All randomized participants who received any dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE's</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival is defined as the time from date of randomization to the date of death from any cause. If the participant is alive at the end of the follow-up period or is lost to follow-up, OS was censored on the last date the participants is known to be alive.</description>
        <time_frame>Baseline to Death From Any Cause (Up to 31 Months)</time_frame>
        <population>All randomized participants who received any dose of study drug. OS data was not analyzed in the crossover olaratumab arm. Participants censored: olaratumab + paclitaxel + carboplatin = 19 and paclitaxel + carboplatin = 20.</population>
        <group_list>
          <group group_id="O1">
            <title>Olaratumab + Paclitaxel + Carboplatin</title>
            <description>Olaratumab: 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered IV at 25mg/min, with a minimum infusion time of 30 minutes.
Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel + Carboplatin</title>
            <description>Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival is defined as the time from date of randomization to the date of death from any cause. If the participant is alive at the end of the follow-up period or is lost to follow-up, OS was censored on the last date the participants is known to be alive.</description>
          <population>All randomized participants who received any dose of study drug. OS data was not analyzed in the crossover olaratumab arm. Participants censored: olaratumab + paclitaxel + carboplatin = 19 and paclitaxel + carboplatin = 20.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3" lower_limit="39.7" upper_limit="68.7"/>
                    <measurement group_id="O2" value="50.1" lower_limit="41.4" upper_limit="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8731</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) Objective Tumor Response Rate (ORR)</title>
        <description>The ORR is equal to the percentage of participants achieving a best overall response of partial response or complete response (PR + CR), according to RECIST version 1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes must have reduction in short axis to &lt;10 millimeter (mm) and normalization of tumor marker level of non-target lesions; PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions; PD was defined as having at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase above nadir; Stable Disease (SD) was defined as small changes that did not meet above criteria. Participants who had no post baseline tumor assessments were considered non-responders and included in the denominator when calculating response rate. Percentage of participants=(number of participants with CR+PR/total number of participants)*100.</description>
        <time_frame>Baseline to Measured PD or Study Discontinuation (Up to 31 Months)</time_frame>
        <population>All randomized participants who received any dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Olaratumab + Paclitaxel + Carboplatin</title>
            <description>Olaratumab: 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered IV at 25mg/min, with a minimum infusion time of 30 minutes.
Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel + Carboplatin</title>
            <description>Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Crossover to Olaratumab</title>
            <description>Olaratumab monotherapy administered on Days 1 and 8 of each 21-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) Objective Tumor Response Rate (ORR)</title>
          <description>The ORR is equal to the percentage of participants achieving a best overall response of partial response or complete response (PR + CR), according to RECIST version 1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes must have reduction in short axis to &lt;10 millimeter (mm) and normalization of tumor marker level of non-target lesions; PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions; PD was defined as having at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase above nadir; Stable Disease (SD) was defined as small changes that did not meet above criteria. Participants who had no post baseline tumor assessments were considered non-responders and included in the denominator when calculating response rate. Percentage of participants=(number of participants with CR+PR/total number of participants)*100.</description>
          <population>All randomized participants who received any dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.8" lower_limit="29.8" upper_limit="54.5"/>
                    <measurement group_id="O2" value="34.4" lower_limit="22.9" upper_limit="47.3"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4721</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Duration of Response</title>
        <description>The duration of overall response is measured from the time measurement criteria are first met for Complete Response (CR)/Partial Response (PR) (whichever is first recorded) until the first date that the criteria for PD are met (taking as a reference for PD the smallest measurement recorded since the treatment started), initiation of other/additional antitumor therapy is first reported, or death, is objectively documented.</description>
        <time_frame>First Criteria Met for CR or PR to Measured PD Start of Other Antitumor Therapy or Death From Any Cause (Up to 31 Months)</time_frame>
        <population>All randomized participants who received any dose of study drug and had achieved tumor response of CR or PR. Median Duration of Response data was not analyzed in the crossover olaratumab arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Olaratumab + Paclitaxel + Carboplatin</title>
            <description>Olaratumab: 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered IV at 25mg/min, with a minimum infusion time of 30 minutes.
Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel + Carboplatin</title>
            <description>Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Duration of Response</title>
          <description>The duration of overall response is measured from the time measurement criteria are first met for Complete Response (CR)/Partial Response (PR) (whichever is first recorded) until the first date that the criteria for PD are met (taking as a reference for PD the smallest measurement recorded since the treatment started), initiation of other/additional antitumor therapy is first reported, or death, is objectively documented.</description>
          <population>All randomized participants who received any dose of study drug and had achieved tumor response of CR or PR. Median Duration of Response data was not analyzed in the crossover olaratumab arm.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" lower_limit="12.7" upper_limit="18.1"/>
                    <measurement group_id="O2" value="12.9" lower_limit="11.4" upper_limit="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics of Olaratumab</title>
        <description>Pharmacodynamics of Olaratumab was determined by analysis of pharmacodynamic markers vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF).</description>
        <time_frame>Cycle 1: Days 1, 8, and 15 pre- and post-infusion of Olaratumab; Cycles 2-6: day 1 only, pre- and post-infusion of Olaratumab</time_frame>
        <population>No data was available due to the collection of plasma samples was not fit for the assessment of PDGFs, as the collection procedure did not prevent platelet activation resulting in elevated levels of PDGFs in the circulation. Pharmacodynamics data was not analyzed in the paclitaxel + carboplatin arm or the crossover to olaratumab arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Olaratumab + Paclitaxel + Carboplatin</title>
            <description>Olaratumab: 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered IV at 25mg/min, with a minimum infusion time of 30 minutes.
Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics of Olaratumab</title>
          <description>Pharmacodynamics of Olaratumab was determined by analysis of pharmacodynamic markers vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF).</description>
          <population>No data was available due to the collection of plasma samples was not fit for the assessment of PDGFs, as the collection procedure did not prevent platelet activation resulting in elevated levels of PDGFs in the circulation. Pharmacodynamics data was not analyzed in the paclitaxel + carboplatin arm or the crossover to olaratumab arm.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-Olaratumab Antibodies</title>
        <description>Participants with Treatment Emergent (TE) anti-olaratumab antibodies were participants with a 4-fold increase (2 dilutions) increase over a positive baseline antibody titer or for a negative baseline titer, a participant with an increase from the baseline to a level of 1:20.</description>
        <time_frame>Baseline to Study Completion (Up to 8 Months)</time_frame>
        <population>All randomized participants who had baseline and post baseline Anti-Olaratumab antibodies. Those participants who did not meet eligibility criteria were not included in this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Olaratumab + Paclitaxel + Carboplatin</title>
            <description>Olaratumab: 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered IV at 25mg/min, with a minimum infusion time of 30 minutes.
Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Crossover to Olaratumab</title>
            <description>Olaratumab monotherapy administered on Days 1 and 8 of each 21-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-Olaratumab Antibodies</title>
          <description>Participants with Treatment Emergent (TE) anti-olaratumab antibodies were participants with a 4-fold increase (2 dilutions) increase over a positive baseline antibody titer or for a negative baseline titer, a participant with an increase from the baseline to a level of 1:20.</description>
          <population>All randomized participants who had baseline and post baseline Anti-Olaratumab antibodies. Those participants who did not meet eligibility criteria were not included in this assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK) - Area Under the Curve (AUC) 0-168 of Olaratumab</title>
        <description>AUC(0-168) = area under the concentration versus time curve from time zero to 168 hours post dose.</description>
        <time_frame>Cycle 3, Day 1: Predose, 30 minutes (min), 1.5 hours (hrs), 24,48,96,168 Hrs Post Dose</time_frame>
        <population>All randomized participants who received any dose of study drug and had evaluable PK data in Cycle 3. PK data was not analyzed in the paclitaxel + carboplatin arm or the crossover to olaratumab arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Olaratumab + Paclitaxel + Carboplatin</title>
            <description>Olaratumab: 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered IV at 25mg/min, with a minimum infusion time of 30 minutes.
Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) - Area Under the Curve (AUC) 0-168 of Olaratumab</title>
          <description>AUC(0-168) = area under the concentration versus time curve from time zero to 168 hours post dose.</description>
          <population>All randomized participants who received any dose of study drug and had evaluable PK data in Cycle 3. PK data was not analyzed in the paclitaxel + carboplatin arm or the crossover to olaratumab arm.</population>
          <units>microgram*hour/milliliter (ug*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47600" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK - Maximum Concentration (Cmax) of Olaratumab</title>
        <time_frame>Cycle 3, Day 1: Predose, 30 min, 1.5 hrs, 24,48,96,168 Hrs Post Dose</time_frame>
        <population>All randomized participants who received any dose of study drug and had evaluable PK data in Cycle 3 first dose. PK data was not analyzed in the paclitaxel + carboplatin arm or the crossover to olaratumab arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Olaratumab + Paclitaxel + Carboplatin</title>
            <description>Olaratumab: 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered IV at 25mg/min, with a minimum infusion time of 30 minutes.
Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>PK - Maximum Concentration (Cmax) of Olaratumab</title>
          <population>All randomized participants who received any dose of study drug and had evaluable PK data in Cycle 3 first dose. PK data was not analyzed in the paclitaxel + carboplatin arm or the crossover to olaratumab arm.</population>
          <units>micrograms/milliliter (ug/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="489" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK - Half-Life (t1/2) of Olaratumab</title>
        <time_frame>Cycle 3, Day 1: Predose, 30 min, 1.5 hrs, 24,48,96,168 Hrs Post Dose</time_frame>
        <population>All randomized participants who received any dose of study drug and had evaluable PK data in Cycle 3 first dose. PK data was not analyzed in the paclitaxel + carboplatin arm or the crossover to olaratumab arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Olaratumab + Paclitaxel + Carboplatin</title>
            <description>Olaratumab: 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered IV at 25 mg/min, with a minimum infusion time of 30 minutes.
Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>PK - Half-Life (t1/2) of Olaratumab</title>
          <population>All randomized participants who received any dose of study drug and had evaluable PK data in Cycle 3 first dose. PK data was not analyzed in the paclitaxel + carboplatin arm or the crossover to olaratumab arm.</population>
          <units>days</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.79" lower_limit="4.29" upper_limit="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK - Clearance (Cl) of Olaratumab</title>
        <time_frame>Cycle 3, Day 1: Predose, 30 min, 1.5 hr, 24,48,96,168 Hrs Post Dose</time_frame>
        <population>All randomized participants who received any dose of study drug and had evaluable PK data in Cycle 3 first dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Olaratumab + Paclitaxel + Carboplatin</title>
            <description>Olaratumab: 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered IV at 25mg/min, with a minimum infusion time of 30 minutes.
Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>PK - Clearance (Cl) of Olaratumab</title>
          <population>All randomized participants who received any dose of study drug and had evaluable PK data in Cycle 3 first dose.</population>
          <units>Liter/hour (L/h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0218" spread="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK - Steady State Volume of Distribution (Vss) of Olaratumab</title>
        <time_frame>Cycle 3, Day 1: Predose, 30 min, 1.5 hrs, 24,48,96,168 Hrs Post Dose</time_frame>
        <population>All randomized participants who received any dose of study drug and had evaluable PK data in Cycle 3 first dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Olaratumab + Paclitaxel + Carboplatin</title>
            <description>Olaratumab: 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered IV at 25mg/min, with a minimum infusion time of 30 minutes.
Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>PK - Steady State Volume of Distribution (Vss) of Olaratumab</title>
          <population>All randomized participants who received any dose of study drug and had evaluable PK data in Cycle 3 first dose.</population>
          <units>Liter (L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.22" spread="9.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Olaratumab + Paclitaxel + Carboplatin</title>
          <description>Olaratumab 15 mg/kg over 30 mins (Days 1 and 8) plus Paclitaxel 200 mg/m2 over 3 hrs (Day 1) Carboplatin AUC=6 (Day 1) of each 21-day cycle
Participants can remain on study after completing chemotherapy and receive olaratumab monotherapy on Days 1 and 8, provided there is ongoing evidence of clinical benefit.
Olaratumab: 15 mg/kg of IMC-3G3 on Days 1 and 8 of each 21-day cycle, administered IV at 25mg/min, with a minimum infusion time of 30 minutes.
Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
        </group>
        <group group_id="E2">
          <title>Paclitaxel + Carboplatin</title>
          <description>Paclitaxel: 200 mg/m2 is then administered IV over 3 hours
Carboplatin: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.</description>
        </group>
        <group group_id="E3">
          <title>Crossover to Olaratumab</title>
          <description>Olaratumab monotherapy administered on Days 1 and 8 of each 21-day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Incorrect drug administration duration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchopleural fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="43" subjects_affected="21" subjects_at_risk="67"/>
                <counts group_id="E2" events="41" subjects_affected="26" subjects_at_risk="64"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="15" subjects_at_risk="67"/>
                <counts group_id="E2" events="17" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="67" subjects_affected="29" subjects_at_risk="67"/>
                <counts group_id="E2" events="37" subjects_affected="17" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="63" subjects_affected="29" subjects_at_risk="67"/>
                <counts group_id="E2" events="31" subjects_affected="15" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="67"/>
                <counts group_id="E2" events="29" subjects_affected="27" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="47" subjects_affected="29" subjects_at_risk="67"/>
                <counts group_id="E2" events="25" subjects_affected="19" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="67"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="58" subjects_affected="34" subjects_at_risk="67"/>
                <counts group_id="E2" events="46" subjects_affected="34" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Oral discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="67"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="36" subjects_affected="28" subjects_at_risk="67"/>
                <counts group_id="E2" events="30" subjects_affected="22" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="75" subjects_affected="43" subjects_at_risk="67"/>
                <counts group_id="E2" events="48" subjects_affected="32" subjects_at_risk="64"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="28" subjects_at_risk="67"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="67"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="43" subjects_affected="25" subjects_at_risk="67"/>
                <counts group_id="E2" events="24" subjects_affected="14" subjects_at_risk="64"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="67"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="67"/>
                <counts group_id="E2" events="21" subjects_affected="15" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="64"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="17" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="67"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="67"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="33" subjects_affected="23" subjects_at_risk="67"/>
                <counts group_id="E2" events="29" subjects_affected="17" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="39" subjects_affected="21" subjects_at_risk="67"/>
                <counts group_id="E2" events="38" subjects_affected="22" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="67"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="67"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="67"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="46" subjects_affected="37" subjects_at_risk="67"/>
                <counts group_id="E2" events="37" subjects_affected="35" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

